Product Description
Mechanisms of Action: EPCAM Antagonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Germany
Approved Indications: None
Known Adverse Events: None
Company: Austrian Breast & Colorectal Cancer Study Group
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Colorectal Cancer|Mucinous Adenocarcinoma|Mucinous Cystadenocarcinoma
Phase 2: Colorectal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| GWCC-5095 | P2 |
Withdrawn |
Colorectal Cancer |
2017-02-22 |
|
| NCI-2012-02826 | P3 |
Completed |
Mucinous Adenocarcinoma|Colorectal Cancer|Mucinous Cystadenocarcinoma |
2003-07-01 |